Get started
Author

James A. Sterchele

Observed names: J Sterchele, J. A. Sterchele, J. Sterchele⁎, J.A. Sterchele⁎, JAMES A. STERCHELE, James Sterchele
OpenAlex ID: A5090782004
Anaphylactoid Reaction following Ketorolac Tromethamine Administration
1992 · Carla M. Goetz, James A. Sterchele, et al. · Annals of Pharmacotherapy · 25
The safety of bendamustine in patients with chronic lymphocytic leukemia or non-Hodgkin lymphoma and concomitant renal impairment: a retrospective electronic medical record database analysis
2013 · Beth L. Nordstrom, Kevin B. Knopf, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 18
Therapeutic Advances in Hematology
2013 · Kathryn S. Kolibaba, James A. Sterchele, et al. · 13
Computer-guided academic detailing as part of a drug benefit program
1995 · Philip W. Keys, Carla M. Goetz, et al. · American Journal of Health-System Pharmacy · 13
Economic implications of using bendamustine, alemtuzumab, or chlorambucil as a first-line therapy for chronic lymphocytic leukemia in the US: a cost-effectiveness analysis
2014 · Thitima Kongnakorn, James Sterchele, et al. · ClinicoEconomics and Outcomes Research · 9
PDF
Demographics, treatment patterns, safety, and real-world effectiveness in patients aged 70 years and over with chronic lymphocytic leukemia receiving bendamustine with or without rituximab: a retrospective study
2013 · Kathryn S. Kolibaba, James A. Sterchele, et al. · Therapeutic Advances in Hematology · 9
Real-World Efficacy and Safety of Bendamustine with or without Rituximab in Treatment-Naive Patients with Chronic Lymphocytic Leukemia: Retrospective Analysis of a German Registry.
2012 · Georg Günther, Stefan Bartels, et al. · Blood · 4
Therapeutic drug monitoring
1990 · David F. Kisor, Varsha Mehta, et al. · Postgraduate Medicine · 3
Cost-effectiveness analysis of bendamustine plus rituximab versus CHOP-R in treatment-naive patients with mantle cell (MCL) and indolent lymphomas (IL).
2012 · Wayne Su, Peter Quon, et al. · Journal of Clinical Oncology · 2
Demographics, Treatment Patterns, Safety, and Real-World Effectiveness in Patients ≥70 Years of Age with Chronic Lymphocytic Leukemia Receiving Bendamustine with or without Rituximab,
2011 · Kathryn S. Kolibaba, Avani D. Joshi, et al. · Blood · 2
Pcn93 Cost-effectiveness Analysis of Bendamustine Compared to Alemtuzumab and Chlorambucil for Chronic Lymphocytic Leukemia in a Treatment-naive Population
2010 · J Malin, T Kongnakorn, et al. · Value in Health · 1
Real-world efficacy and safety of bendamustine with or without rituximab in treatment-naïve older patients with chronic lymphocytic leukemia: Retrospective analysis by age group from a German registry
2012 · G. Günther, S. Bartels, et al. · Journal of Geriatric Oncology
Bendamustine in patients with renal impairment: A real-world, retrospective safety assessment
2012 · B. Nordstrom, K. Knopf, et al. · Journal of Geriatric Oncology
Retrospective safety assessment of bendamustine in patients with renal impairment.
2012 · Beth L Nordstrom, Kevin B. Knopf, et al. · Journal of Clinical Oncology
Improving Drug Use Through Purchase Agreement Commitments
1993 · Philip Keys, Raymond C. Stierer, et al. · American Journal of Health-System Pharmacy
Room-temperature stability of allergenic extracts
1991 · James A. Sterchele, Raymond C. Stierer · American Journal of Health-System Pharmacy
Cimetidine and ß-Blockers
1989 · JAMES A. STERCHELE · Archives of Internal Medicine
Cimetidine and beta-blockers
1989 · J. A. Sterchele · Archives of Internal Medicine
Correction: Pharm.D. program listing
1988 · James A. Sterchele, David F. Kisor · Annals of Pharmacotherapy
PDF
Works count: 19
Citation count: 99
H-index: 6
I10-index: 4
Year
Topic
Type